Search

Viral vector manufacture has come a long way, but the story is far from over.

Clinical trials suffer from heavy dropout rates. Perhaps the answer is a little care and attention.

How can multi-column chromatography support companies as they set their sights on intensified bioprocesses?

We sat down to talk shop with Novo Nordisk Executive Vice President Ludovic Helfgott

We find out how technology is enabling remote inspections in the pharma industry.

That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?

Are all antibiotics doomed to eventual impotence? New work from Oxford could change the game by defeating resistance itself.

Sitting Down With Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene.

Thorben Seeger wants to democratize the data held by the world’s leading genomic institutions. But what exactly does he mean by “democratize”?

The Russian invasion of Ukraine will disrupt and displace a great deal of work in drug discovery. Here’s why.